Search Results

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe.

Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation.

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.

Stallergenes Greer, a biopharmaceutical company specialising in the diagnosis and treatment of respiratory allergies, announced today the initiation of a Phase III clinical study (YOBI, YOung patients and BIrch allergy) to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis with or without asthma.

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, will be hosting a company-sponsored symposium entitled “Patient’s perspective: A must have for the future of Allergen Immunotherapy” at the 2023 European Academy of Allergy and Clinical Immunology Congress taking place June 9-11 in Hamburg.

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, announced the launch of CORAP.

Stallergenes Greer, today announced that the company has entered into an exclusive partnership with Aptar Pharma, for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.

Stallergenes Greer today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.